Genetic and immunologic susceptibility to statin-related myopathy

Atherosclerosis

Volumn 240, Issue 1, 2015, Pages 260-271

  Patel, Jaideep ^a,b   Superko, H Robert ^c,d   Martin, Seth S ^a   Blumenthal, Roger S ^a   Christopher Stine, Lisa ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MERCER UNIVERSITY   (United States)

^d Cholesterol Genetics and Heart Disease Institute   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Anti HMGCR; Pharmacogenomics; SLCO1B1; Statin related myopathy

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; CERIVASTATIN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FLUINDOSTATIN; HLA DRB1 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; ORGANIC ANION TRANSPORTER B; PRAVASTATIN; ROSUVASTATIN; RYANODINE RECEPTOR 1; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; GENETIC MARKER;

DRUG METABOLISM; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MYOPATHY; PHARMACODYNAMICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; ANIMAL; CARDIOMYOPATHY; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; HEART MUSCLE CELL; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHARMACOGENETICS; PHENOTYPE; RISK FACTOR;

ANIMALS; CARDIOMYOPATHIES; GENE EXPRESSION REGULATION; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCYTES, CARDIAC; PHARMACOGENETICS; PHENOTYPE; RISK FACTORS;

EID: 84925396361     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.03.025     Document Type: Review

References (109)

1. Stone N.J., Robinson J., Lichtenstein A.H., Merz C.N., Blum C.B., Eckel R.H., Goldberg A.C., Gordone D., Levy D., Lloyd-Jones D.M., McBride P., Schwartz J.S., Shero S.T., Smith S.C., Watson K., Wilson P.W. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2014, 129(25 Suppl.2):S1-S45.
2. Andrade S.E., Walker A.M., Gottlieb L.K., Hollenberg N.K., Testa M.A., Saperia G.M., Platt R. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings?. N.Engl. J. Med. 1995, 332:1125-1131.
3. Sewright K.A., Clarkson P.M., Thompson P.D. Statin myopathy: incidence, risk factors, and pathophysiology. Curr. Atheroscler. Rep. 2007, 9:389-396.
4. McKenney J.M., Davidson M.H., Jacobson T.A., Guyton J.R. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am. J. Cardiol. 2006, 97:89C-94C. National Lipid Association Statin Safety Assessment Task Force.
5. Pasternak R.C., Smith S.C., Bairey Merz C.N., Grundy S.M., Cleeman J.I., Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J.Am. Coll. Cardiol. 2002, 40:567-572. American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute.
6. Kashani A., Phillips C.O., Foody J.M., Wang Y., Mangalmurti S., Ko D.T., Krumholz H.M. Risk associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006, 114(25):2788-2797.
7. Nichols G.A., Koro C.E. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin. Ther. 2007, 29(8):1761-1770.
8. Bruckert E., Havem G., Dejager S., Yau C., Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc. Drugs Ther. 2005, 19(6):403-414.
9. Buettner C., Davis R.B., Leveille S.G., Mittleman M.A., Mukamal K.J. Prevalence of musculoskeletal pain and statin use. J.Gen. Intern. Med. 2008, 23(8):1182-1186.
10. Parker B.A., Capizzi J.A., Grimaldi A.S., Clarkson P.M., Cole S.M., Keadle J., Chipkin S., Pescatello L.S., Simpson K., White C.M., Thompson P.D. Effect of statins on skeletal muscle function. Circulation 2013, 127:96-103.
11. Bohan A., Peter J.B. Polymyositis and dermatomyositis (first of two parts). N.Engl. J. Med. 1975, 292(7):344-347.
12. Bohan A., Peter J.B. Polymyositis and dermatomyositis (second of two parts). N.Engl. J. Med. 1975, 29(8):403-407.
13. McClure D.L., Valuck R.J., Glanz M., Murphy J.R., Hokanson J.E. Statin and statin-fibrate use was significantly associated with increased myositis risk in a man-aged care population. J.Clin. Epidemiol. 2007, 60:812-818.
14. Jacobson T.A. Statin safety: lessons from new drug applications for marketed statins. Am. J. Cardiol. 2006, 97(8A):44C-451C.
15. Needham M., Mastaglia F.L. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul. Disord. 2014, 24:4-15.
16. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther. 2010, 87(1):130-133.
17. Bjorkhem-Bergman L., Bergstrom H., Johansson M., Parini P., Eriksson M., Rane A., Ekström L. Atorvastatin treatment induces uptake and efflux transporters in human liver. Drug Metab. Dispos. 2013, 41(9):1610-1615.
18. Keskitalo J.E., Pasanen M.K., Neuvonen P.J., Niemi M. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 2009, 10:1617-1624.
19. Ferrari M., Guasi L., Maresca A., Mirabile M., Contini S., Grandi A.M., Marino F., Cosentino M. Association between statin-induced creatine kinase elevation and gene polymorphism in SLCO1B1, ABCB1 and ABCG2. Eur. J. Clin. Pharmacol. 2014, 70(5):539-547.
20. Fiegenbaum M., Da Silveira F.R., Van der Sand Cr, Van der Sand L.C., Ferreira M.E., Pires R.C., Hutz M.H. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharamcol. Ther. 2005, 78(5):551-558.
21. Hoenig M.R., Walker P.J., Gurnsey C., Beadle K., Johnson L. The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. J.Clin. Lipidol. 2011, 5(2):91-96.
22. Donnelly L.A., Doney A.S., Tavendale R., Lang C.C., Peason E.R., Colhoun H.M., McCarthy M.I., Hattersley A.T., Morris A.D., Palmer C.N. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin. Pharmacol. Ther. 2011, 89:210-216.
23. Pasanen M.K., Fredrikson H., Neuvonen P.J., Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 2007, 82(6):726-733.
24. Pasanen M.K., Neuvonen M., Neuvonen P.J., Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharm. Genomics 2006, 16:873-879.
25. Niemi M., Pasanen M.K., Neuvonen P.J. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 2006, 80(4):356-366.
26. Link E., Parish S., Armitage J., Bowman L., Heath S., Matsuda F., Gut I., Lathrop M., Collins R. SLCO1B1 variants and statin-induced myopathy - a genome wide study. N.Engl. J. Med. 2008, 359(8):789-799. SEARCH Collaborative Group.
27. Brunham L.R., Lansberg P.J., Xhang L., Miao F., Carter C., Hovingh G.K., Visscher H., Jukema J.W., Stalenhoef A.F., Ross C.J., Carleton B.C., Kastelein J.J., Haden M.R. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharm. J. 2012, 12(3):233-237.
28. Marciante K.D., Durda J.P., Heckbert S.R., Lumley T., Rice K., McKnight B., Totah R.A., Tamraz B., Kroetz D.L., Fukushima H., Kaspera R., Bis J.C., Glazer N.L., Li G., Austin T.R., Taylor K.D., Rotter J.I., Jaquish C.E., Kwok P.Y., Tracy R.P., Psaty B.M. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharm. Genomics 2011, 21(5):280-288.
29. Linde R., Peng L., Desai M., Feldman D. The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias. Dermatoendocrinol 2010, 2(2):77-84.
30. Carr D.F., O'Meara H., Jorgensen A.L., Campbell J., Hobbs M., McCann G., van Staa T., Pirmogamed M. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin. Pharamachol. Ther. 2013, 94(6):695-771.
31. Santos P.C., Gagliardi A.C., Miname M.H., Chacra A.P., Santos R.D., Kriedger J.E., Pereira A.C. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur. J. Clin. Pharmacol. 2012, 68(3):273-279.
32. Danik J.S., Chasman D.L., MacFadyen J.G., Nyberg F., Barratt B.J., Ridker P.M. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am. Heart J. 2013, 165(6):1008-1014.
33. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group.
34. Voora D., Shah S.H., Spasojevic I., Ali S., Reed C.R., Salisbury B.A., Ginsburg G.S. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J.Am. Coll. Cardiol. 2009, 54(17):1609-1616.
35. de Keyser C.E., et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharm. Genomics 2014, 24:43-51.
36. Hopewell J.C., Parish S., Offer A., Link E., Clarke R., lathrop M., Amritage J., Collins R. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur. Heart J. 2013, 34:982-992. MRC/BHF Heart Protection Study Collaborative Group.
37. Chasman D.I., Giulianini F., MacFadyen J., et al. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the justification for the use of statins in prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial. Circ. Cardiovasc. Genet. 2012, 5:257-264.
38. Akao H., Polisecki E., Kajinami K., Trompet S., Robertson M., Ford I., Jkema J.W., de Craen A.J., Westendorp R.G., Shepherd J., Packard C., Buckley B.M., Schaefer E.J. Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly. Atherosclerosis 2012, 220:413-417.
39. Gryn Se, Hegele R.A. Pharmacogenomics, lipid disorders, and treatment options. Clin. Pharmacol. Ther. 2014, 96(1):36-47.
40. Thompson J.F., Man M., Johnson K.J., Wood L.S., Lira M.E., Lloyd D.B., Banerjee P., Milos P.M., Myrand S.P., Paulauskis J., Milad M.A., Sasiela W.J. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharm. J. 2005, 5:352-358.
41. FDA FDA Announces New Safety Recommendations for High-dose Simvastatin 2011, Available at:, (accessed 03.03.14.). http://www.fda.gov/newsevents/newsroom/pressannouncements/2011/ucm258338.htm.
42. Wilke R.A., Ramsey L.B., Johnson S.G., Maxwell W.D., McLeod H.L., Voora D., Krauss R.M., Roden D.M., Feng Q., Cooper-Dehoff R.M., Gong L., Klein T.E., Wadelius M., Niemi M. The Clinical Pharmacogenomics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 2012, 92:112-117.
43. Patel J., Abd T., Blumenthal R.S., Nasir K., Superko H.R. Genetics and personalized medicine-a role in statin therapy?. Curr. Atheroscler. Rep. 2014, 16(1):384.
44. Mancini G.B., Tashakkor A.Y., Baker S., Bergeron J., Fitchett D., Frohlich J., Genest J., Gupta M., Hegele R.A., Ng D.S., Pearson G.J., Pope J. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can. J. Cardiol. 2013, 29:1553-1568.
45. Abd T.A., Jacobson T.A. Statin-induced myopathy: a review and update. Expert Opin. Drug Saf. 2011, 10(3):373-387.
46. Golomb B.A., Evans M.A. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am. J. Cardiovasc. Drugs 2008, 8(6):373-418.
47. Nordin C., Dahl M.L., Eriksson M., Sjoberg S. Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?. Lancet 1997, 350:29-30.
48. Saschse C., Brockmoller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 1997, 60:284-295.
49. Mulder A.B., van Lijf H.J., Bon M.A., van den Bergh F.A., Touw D.J., Neef C., Vermes I. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin. Pharmacol. Ther. 2001, 70(6):546-551.
50. Frudakis T.N., Thomas M.J., Ginjupalli S.N., Handelin B., Gabriel R., Gomez H.J. CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharm. Genomics 2007, 17(9):695-707.
51. Vermes A., Vermes I. Genetic polymorphism in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am. J. Cardiovasc. Drugs 2004, 4(4):247-255.
52. Bellosta S., Paoletti R., Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004, 109(23 Suppl.1):III50-III57.
53. Fallah A., Deep M., Smallwood D., Hughes P. Life-threatening rhabdomyolysis following the interaction of two commonly prescribed medications. Australas. Med. J. 2013, 6(3):112-114.
54. Thummel K.E., Wilkinson G.R. Invitro and invivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 1998, 38:389-430.
55. Abbott A. With your genes? Take one of these, three times a day. Nature 2003, 425(6960):760-762.
56. Wilke R.A., Moore J.H., Burmester J.K. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharm. Genomics 2005, 15(6):415-421.
57. Wang B., Yang L.P., Zhang X.Z., Huang S.Q., Bartlam M., Zhou S.F. New insight into the structural characteristics and functional relevance of humane cytochrome P450 2D6 enzyme. Drug Metab. Rev. 2009, 41(4):573-643.
58. Zuccaro P., Mombelli G., Calabresi L., Baldassarre D., Palmi I., Sirtori C.R. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol. Res. 2007, 55(4):310-317.
59. Marez D., Legrand M., Sabbagh N., Lo Guidice J.M., Spire C., Lafitte K.K., Meyer U.A., Broly F. Polymorphisms of the cytochrome P450 CYP2D6 gene in European population: characterization of 48 mutations and 53 alleles, their frequency, and evolution. Pharmacogentic 1997, 7:193-202.
60. Harris L.J., Thapa R., Brown M., et al. Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia. J.Clin. Lipidol. 2011, 5:299-307.
61. Ghatak A., Faheem O., Thompson P.D. The genetics of statin-induced myopathy. Atherosclerosis 2010, 210:337-353.
62. Ruano G., Windermuth A., Wu A.H., Kane J.P., Malloy M.J., Pullinger C.R., Kocherla M., Bogaard K., Gordon B.R., Holford T.R., Gupta A., Seip R.L., Thompson P.D. Mechanisms of statin-induced myalgia assessed by physiogenomic associations. Atherosclerosis 2011, 218(2):451-456.
63. Mangravite L.M., Engelhardt B.E., Medina M.W., Smith J.D., Brown C.D., Chasman D.I., Mecham B.H., Howie B., Shim H., Naidoo D., Feng Q., Rieder M.J., Chen Y.D., Rotter J.I., Ridker P.M., Hopewell J.C., Parish S., Armitage J., Collins R., Wilke R.A., Nickerson D.A., Stephens M., Krauss R.M. Astatin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 2013, 502(7471):377-380.
64. Thompson P.D., Clarkson P., Karas R.H. Statin-associated myopathy. JAMA 2003, 289(13):1681-1690.
65. Marcoff L., Thompson P.D. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J.Am. Coll. Cardiol. 2007, 49(23):2231-2237.
66. Oh J., Ban M.R., Miskie B.A., Pollex R.L., Hegele R.A. Genetic determinants of statin intolerance. Lipids Health Dis. 2007, 6:7.
67. Puccetti L., Ciani F., Auteri A. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010, 211(1):28-29.
68. Kelly P., Vaso S., Gelato M., McNurlan M., Lawson W. Coenzyme Q10 improves myopathic pain in statin treated patients [abstract]. J.Am. Coll. Cardiol. 2005, 45(3 Suppl.A):3A.
69. Young J.M., Florkowski C.M., Molyneux S.L., McEwan R.G., Fampton C.M., George P.M., Scott R.S. Coenzyme Q10 does not improve simvastatin tolerability in dyslipidemic patients with prior statin-induced myalgia. Circulation 2007, 100(9):1400-1403.
70. Caso G., Kelly P., McNurlan M.A., Lawson W.E. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am. J. Cardiol. 2007, 99(10):1409-1412.
71. Wyman M., Leonard M., Morledge T. Coenzyme Q10: a therapy for hypertension and statin-induced myalgia?. Cleve. Clin. J. Med. 2010, 77(7):435-442.
72. Vladutiu G.D., Simmons Z., Isackson P.J., Tarnopolsky M., Peltier W.L., Barbol A.C., Sripathi N., Wortmann R.L., Phillips P.S. Genetic risk factors and metabolic myopathic symptoms associated with lipid-lowering drugs. Muscle Nerve 2006, 34:153-162.
73. Thomas J.E., Lee N., Thompson P.D. Statins provoking MELAS syndrome. A case report. Eur. Neurol. 2007, 57:232-235.
74. Chariot P., Abadia R., Agnus D., Danan C., Charpentier C., Gherardi R.K. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am. J. Med. 1993, 94:109-110.
75. Tay S.K., DiMauro S., Pang A.Y., Lai P.S., Yap H.K. Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation. Pediatr. Neurol. 2008, 39:426-428.
76. Mammen A.L., Amato A.A. Statin myopathy: a review of recent progress. Curr. Opin. Rhematol. 2010, 22:644-650.
77. Needham M., Fabian V., Knezevic W., Panegyres P., Zilko P., Mastaglia F.L. Progressive myopathy with upregulation of MHC-I associated with statin therapy. Neuromuscul. Disord. 2007, 17(2):194-200.
78. Grable-Esposito P., Katzberg H.D., Greenberg S.A., Srinivasan J., Katz J., Amato A.A. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010, 41(2):185-190.
79. Christopher-Stine L., Casciola-Rosen L.A., Hong G., Chung T., Corse A.M., Mammen A.L. Anovel autoantibody recognizing 200k and 100-kd proteins is associated with an immune- mediated necrotizing myopathy. Arthr. Rheum. 2010, 62(9):2757-2766.
80. Werner J.L., Christopher-Stine L., Ghazarian S.R., Pak K.S., Kus J.E., Daya N.R., Lloyd T.E., Mammen A.L. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthr. Rheum. 2012, 64(12):4087-4093.
81. Mammen A.L., Chung T., Christopher-Stine L., Rosen P., Rosen A., Doering K.R., Casciola-Rosen L.A. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase (HMGCR) in patients with statin-associated autoimmune myopathy. Arthr. Rheum. 2011, 63(3):713-721.
82. RDL Reference Library Anti-HMGCR Autoantibodies, (PDF) 2014, Available at:, (accessed 29.03.14.). http://www.rdlinc.com/rdlinc/wp-content/uploads/2014/02/Anti-HMGCR_Autoantibodies_February_2014.pdf.
83. Mammen A.L., Gaudet D., Brisson D., Chirstopher-Stine L., Lloyd T.E., Leffell M.S., Zachary A.A. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-conenzyme A reductase-associated autoimmune myopathy. Arthr. Car Res. 2012, 64(8):1233-1237.
84. Gough S.C.L., Simmonds M.J. The HLA region and autoimmune disease: associations and mechanisms of action. Curr. Genomics 2007, 8(7):453-465.
85. McKenney J.M., Davidson M.H., Jacobson T.A., Guyton J.R. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am. J. Cardiol. 2006, 97(Suppl.l):89C-94C.
86. Mancini G.B., Baker S., Bergeron J., Fitchett D., Frohlich J., Genest J., Gupta M., Hegele R.A., Ng D., Pope J. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus conference. Can. J. Cardiol. 2011, 27(5):635-662.
87. Peter B.J., Klungel O.H., Visseren F.L., de Boer A., Maitland-van der Zee A.H. Pharmacogenomic insights into treatment and management of statin-induced myopathy. Genome Med. 2009, 1(12):120.
88. Carr D.F., Alfirevic A., Johnson R., Chinoy H., van Staa T., Pirmohamed M. GATM gene variants and statin myopathy risk. Nature 2014, 513(7518):E1.
89. Floyd J.S., Bis J.C., Brody J.A., Heckbert S.R., Rice K., Psaty B.M. GATM locus does not replicate in rhabdomyolysis study. Nature 2014, 513(7518):E1-E3.
90. Stone N.J., Robinson J.G., Lichtenstein A.H., Bairey Merz C.N., Blum C.B., Eckel R.H., Goldberg A.C., Gordon D., Levy D., Lloyd-Jones D.M., McBride P., Schwartz J.S., Shero S.T., Smith S.C., Watson K., Wilson P.W. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J.Am. Coll. Cardiol. 2014, 63(25 Pt B):2889-2934. American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
91. Mammen A.L., Pak K., Williams E.K., et al. Rarity of anti-3-hydroxy-3- methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthr. Care Res. Hob. 2012, 64:269-272.
92. Ruof J., Klein G., Marz W., Wollschlager H., Neiss A., Wehling M. Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns. Prev. Med. 2002, 35:48-53.
93. Svilaas A., Risberg K., Thoresen M., Ose L. Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice. Am. J. Cardiol. 2000, 86:1250-1253. A6.
94. Zhang H., Plutzky J., Skentzos S., et al. Discontinuation of statins in routine care settings: a cohort study. Ann. Intern. Med. 2013, 158:526-534.
95. Mampuya W.M., Frid D., Rocco M., et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am. Heart J. 2013, 166:597-603.
96. Glueck C.J., Aregawi D., Agloria M., et al. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Clin. Ther. 2006, 28:933-942.
97. Backes J.M., Venero C.V., Gibson C.A., et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann. Pharmacother. 2008, 42:341-346.
98. Harper C.R., Jacobson T.A. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr. Opin. Lipidol. 2007, 18:401-408.
99. Bays H. Statin safety: an overview and assessment of the data-2005. Am. J. Cardiol. 2006, 97:6C-26C.
100. Stein E.A., Ballantyne C.M., Windler E., et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am. J. Cardiol. 2008, 101:490-496.
101. Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., Agewall S., Alegria E., Chapman M.J., Durrington P., Erdine S., Halcox J., Hobbs R., Kjekshus J., Filardi P.P., Riccardi G., Storey R.F., Wood D. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011, 32(14):1769-1818.
102. Ioannidis J.P.A. More than a billion people taking statins? Potential implications of the new cardiovascular guidelines. JAMA 2014, 311(5):463-464.
103. Vladutiu G.D., Isackson P.J., Kaufman K., Harley J.B., Cobb B., Christopher-Stine L., Wortman R.L. Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies. Mol. Genet. Metab. 2011, 104:167-173.
104. Hanai J., Cao P., Tanksale P., Imamura S., Koshimizu E., Zhao J., Kishi S., Yamashita M., Phillips P.S., Sukatme V.P., Lecker S.H. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J.Clin. Invest. 2007, 117(12):3940-3951.
105. Ruano G., Thompson P.D., Windemuth A., Seip R.L., Dande A., Sorokin A., Kocherla M., Smith A., Holford T.R., Wu A.H. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve 2007, 36(3):329-335.
106. Superko H.R., Momary K.M., Li Y. Statins personalized. Med. Clin. N. Am. 2012, 96(1):123-139.
107. Padala S., Thompson P.D. Statins as a possible cause of inflammatory and necrotizing myopathies. Atherosclerosis 2012, 222(1):15-21.
108. Eckel R.H. Approach to the patient who is intolerant of statin therapy. J.Clin. Endocrinol. Metab. 2010, 95(5):2015-2022.
109. Thompson P.D., Clarkson P.M., Rosenson R.S. An assessment of statin safety by muscle experts. Am. J. Cardiol. 2006, 97:69C-76C.